Overexpression of inhibitor of DNA-binding (ID)-1 protein related to angiogenesis in tumor advancement of ovarian cancers

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Maw, Min K ^a   Fujimoto, Jiro ^a   Tamaya, Teruhiko ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; INHIBITOR OF DIFFERENTIATION 1; INHIBITOR OF DIFFERENTIATION 2; INHIBITOR OF DIFFERENTIATION 3; MESSENGER RNA; VON WILLEBRAND FACTOR; ID1 PROTEIN, HUMAN; ID2 PROTEIN, HUMAN; ID3 PROTEIN, HUMAN; INHIBITOR OF DIFFERENTIATION PROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GYNECOLOGIC SURGERY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROVASCULATURE; OVARY CANCER; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; BIOSYNTHESIS; DISEASE COURSE; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; PATHOLOGY;

ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF DIFFERENTIATION PROTEIN 1; INHIBITOR OF DIFFERENTIATION PROTEIN 2; INHIBITOR OF DIFFERENTIATION PROTEINS; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 73249138012     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-430     Document Type: Article

References (44)

1. Norton JD, Deed RW, Craggs G, Sablitzky F. Id helix-loop-helix proteins in cell growth and differentiation. Trends Cell Biol 1998, 8(2):58-65. 10.1016/S0962-8924(97)01183-5, 9695810.
2. Riechmann V, Sablitzky F. Mutually exclusive expression of two dominant-negative helix-loop-helix (dnHLH) genes, Id4 and Id3, in the developing brain of the mouse suggests distinct regulatory roles of these dnHLH proteins during cellular proliferation and differentiation of the nervous system. Cell Growth Differ 1995, 6(7):837-843.
3. Riechmann V, van Cruchten I, Sablitzky F. The expression pattern of Id4, a novel dominant negative helix-loop-helix protein, is distinct from Id1, Id2 and Id3. Nucleic Acids Res 1994, 22(5):749-755. 10.1093/nar/22.5.749, 307878, 8139914.
4. Benezra R, Rafii S, Lyden D. The Id proteins and angiogenesis. Oncogene 2001, 20(58):8334-8341. 10.1038/sj.onc.1205160, 11840326.
5. Fong S, Debs RJ, Desprez PY. Id genes and proteins as promising targets in cancer therapy. Trends Mol Med 2004, 10(8):387-392. 10.1016/j.molmed.2004.06.008, 15310459.
6. Hasskarl J, Munger K. Id proteins--tumor markers or oncogenes?. Cancer Biol Ther 2002, 1(2):91-96.
7. Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM. Id proteins in cell growth and tumorigenesis. Cancer Cell 2003, 3(6):525-530. 10.1016/S1535-6108(03)00141-7, 12842081.
8. Wong YC, Wang X, Ling MT. Id-1 expression and cell survival. Apoptosis 2004, 9(3):279-289. 10.1023/B:APPT.0000025804.25396.79, 15258459.
9. Zebedee Z, Hara E. Id proteins in cell cycle control and cellular senescence. Oncogene 2001, 20(58):8317-8325. 10.1038/sj.onc.1205092, 11840324.
10. Alani RM, Hasskarl J, Grace M, Hernandez MC, Israel MA, Munger K. Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id-1. Proc Natl Acad Sci USA 1999, 96(17):9637-9641. 10.1073/pnas.96.17.9637, 22262, 10449746.
11. Norton JD, Atherton GT. Coupling of cell growth control and apoptosis functions of Id proteins. Mol Cell Biol 1998, 18(4):2371-2381. 121494, 9528806.
12. Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y, Sharrocks AD, Peters G, Hara E. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 2001, 409(6823):1067-1070. 10.1038/35059131, 11234019.
13. Ouyang XS, Wang X, Ling MT, Wong HL, Tsao SW, Wong YC. Id-1 stimulates serum independent prostate cancer cell proliferation through inactivation of p16(INK4a)/pRB pathway. Carcinogenesis 2002, 23(5):721-725. 10.1093/carcin/23.5.721, 12016143.
14. Prabhu S, Ignatova A, Park ST, Sun XH. Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. Mol Cell Biol 1997, 17(10):5888-5896. 232436, 9315646.
15. Everly DN, Mainou BA, Raab-Traub N. Induction of Id1 and Id3 by latent membrane protein 1 of Epstein-Barr virus and regulation of p27/Kip and cyclin-dependent kinase 2 in rodent fibroblast transformation. J Virol 2004, 78(24):13470-13478. 10.1128/JVI.78.24.13470-13478.2004, 533955, 15564458.
16. Perk J, Iavarone A, Benezra R. Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 2005, 5(8):603-614. 10.1038/nrc1673, 16034366.
17. Alani RM, Young AZ, Shifflett CB. Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a. Proc Natl Acad Sci USA 2001, 98(14):7812-7816. 10.1073/pnas.141235398, 35424, 11427735.
18. Le Jossic C, Ilyin GP, Loyer P, Glaise D, Cariou S, Guguen-Guillouzo C. Expression of helix-loop-helix factor Id-1 is dependent on the hepatocyte proliferation and differentiation status in rat liver and in primary culture. Cancer Res 1994, 54(23):6065-6068.
19. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, Bader BL, Hynes RO, Zhuang Y, Manova K. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999, 401(6754):670-677. 10.1038/44334, 10537105.
20. Ouyang XS, Wang X, Lee DT, Tsao SW, Wong YC. Over expression of ID-1 in prostate cancer. J Urol 2002, 167(6):2598-2602. 10.1016/S0022-5347(05)65044-6, 11992094.
21. Yuen HF, Chua CW, Chan YP, Wong YC, Wang X, Chan KW. Id proteins expression in prostate cancer: high-level expression of Id-4 in primary prostate cancer is associated with development of metastases. Mod Pathol 2006, 19(7):931-941. 10.1038/modpathol.3800602, 16575399.
22. Fong S, Itahana Y, Sumida T, Singh J, Coppe JP, Liu Y, Richards PC, Bennington JL, Lee NM, Debs RJ. Id-1 as a molecular target in therapy for breast cancer cell invasion and metastasis. Proc Natl Acad Sci USA 2003, 100(23):13543-13548. 10.1073/pnas.2230238100, 263850, 14578451.
23. Jang KS, Han HX, Paik SS, Brown PH, Kong G. Id-1 overexpression in invasive ductal carcinoma cells is significantly associated with intratumoral microvessel density in ER-negative/node-positive breast cancer. Cancer Lett 2006, 244(2):203-210. 10.1016/j.canlet.2005.12.016, 16469432.
24. Jang TJ, Jung KH, Choi EA. Id-1 gene downregulation by sulindac sulfide and its upregulation during tumor development in gastric cancer. Int J Cancer 2006, 118(6):1356-1363. 10.1002/ijc.21503, 16184548.
25. Tsuchiya T, Okaji Y, Tsuno NH, Sakurai D, Tsuchiya N, Kawai K, Yazawa K, Asakage M, Yamada J, Yoneyama S. Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancer. Cancer Sci 2005, 96(11):784-790. 10.1111/j.1349-7006.2005.00113.x, 16271072.
26. Yuen HF, Chan YP, Chan KK, Chu YY, Wong ML, Law SY, Srivastava G, Wong YC, Wang X, Chan KW. Id-1 and Id-2 are markers for metastasis and prognosis in oesophageal squamous cell carcinoma. Br J Cancer 2007, 97(10):1409-1415. 10.1038/sj.bjc.6604035, 2360242, 18000500.
27. Maw MK, Fujimoto J, Tamaya T. Expression of the inhibitor of DNA-binding (ID)-1 protein as an angiogenic mediator in tumour advancement of uterine cervical cancers. Br J Cancer 2008, 99(10):1557-1563. 10.1038/sj.bjc.6604722, 2584935, 19002177.
28. Schindl M, Schoppmann SF, Strobel T, Heinzl H, Leisser C, Horvat R, Birner P. Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin Cancer Res 2003, 9(2):779-785.
29. International Federation of Obstetrics and Gynecology (FIGO) News. Int J Gynecol Obstet 1989, 28:189-193. FIGO News, 10.1016/0020-7292(89)90482-7.
30. McCarty KS, Miller LS, Cox EB, Konrath J, McCarty KS. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med 1985, 109(8):716-721.
31. Giatromanolaki A, Sivridis E, Brekken R, Thorpe PE, Anastasiadis P, Gatter KC, Harris AL, Koukourakis MI. The angiogenic "vascular endothelial growth factor/flk-1(KDR) receptor" pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Cancer 2001, 92(10):2569-2577. 10.1002/1097-0142(20011115)92:10<2569::AID-CNCR1609>3.0.CO;2-3, 11745191.
32. Maeda K, Chung YS, Ogawa Y, Takatsuka S, Kang SM, Ogawa M, Sawada T, Onoda N, Kato Y, Sowa M. Thymidine phosphorylase/platelet-derived endothelial cell growth factor expression associated with hepatic metastasis in gastric carcinoma. Br J Cancer 1996, 73(8):884-888. 2075824, 8611421.
33. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987, 162(1):156-159. 10.1016/0003-2697(87)90021-2, 2440339.
34. Lin CQ, Singh J, Murata K, Itahana Y, Parrinello S, Liang SH, Gillett CE, Campisi J, Desprez PY. A role for Id-1 in the aggressive phenotype and steroid hormone response of human breast cancer cells. Cancer Res 2000, 60(5):1332-1340.
35. Maruyama H, Kleeff J, Wildi S, Friess H, Buchler MW, Israel MA, Korc M. Id-1 and Id-2 are overexpressed in pancreatic cancer and in dysplastic lesions in chronic pancreatitis. Am J Pathol 1999, 155(3):815-822. 1866883, 10487839.
36. Ling MT, Lau TC, Zhou C, Chua CW, Kwok WK, Wang Q, Wang X, Wong YC. Overexpression of Id-1 in prostate cancer cells promotes angiogenesis through the activation of vascular endothelial growth factor (VEGF). Carcinogenesis 2005, 26(10):1668-1676. 10.1093/carcin/bgi128, 15905202.
37. Cheung HW, Ling MT, Tsao SW, Wong YC, Wang X. Id-1-induced Raf/MEK pathway activation is essential for its protective role against taxol-induced apoptosis in nasopharyngeal carcinoma cells. Carcinogenesis 2004, 25(6):881-887. 10.1093/carcin/bgh087, 14742319.
38. Lin JC, Chang SY, Hsieh DS, Lee CF, Yu DS. The association of Id-1, MIF and GSTpi with acquired drug resistance in hormone independent prostate cancer cells. Oncol Rep 2005, 13(5):983-988.
39. Zhang X, Ling MT, Wang X, Wong YC. Inactivation of Id-1 in prostate cancer cells: A potential therapeutic target in inducing chemosensitization to taxol through activation of JNK pathway. Int J Cancer 2006, 118(8):2072-2081. 10.1002/ijc.21592, 16287090.
40. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16(9):4604-4613. 231459, 8756616.
41. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359(6398):843-845. 10.1038/359843a0, 1279431.
42. Kim HJ, Chung H, Yoo YG, Kim H, Lee JY, Lee MO, Kong G. Inhibitor of DNA binding 1 activates vascular endothelial growth factor through enhancing the stability and activity of hypoxia-inducible factor-1alpha. Mol Cancer Res 2007, 5(4):321-329. 10.1158/1541-7786.MCR-06-0218, 17426247.
43. Fujimoto J, Alam SM, Jahan I, Sato E, Toyoki H, Hong BL, Sakaguchi H, Tamaya T. Plausible linkage of hypoxia inducible factor-1alpha in uterine cervical cancer. Cancer Sci 2006, 97(9):861-867. 10.1111/j.1349-7006.2006.00262.x, 16805819.
44. Volpert OV, Pili R, Sikder HA, Nelius T, Zaichuk T, Morris C, Shiflett CB, Devlin MK, Conant K, Alani RM. Id1 regulates angiogenesis through transcriptional repression of thrombospondin-1. Cancer Cell 2002, 2(6):473-483. 10.1016/S1535-6108(02)00209-X, 12498716.